Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Assets (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Current Assets for 16 consecutive years, with $605000.0 as the latest value for Q4 2025.

  • Quarterly Current Assets fell 49.46% to $605000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $605000.0 through Dec 2025, down 49.46% year-over-year, with the annual reading at $605000.0 for FY2025, 49.46% down from the prior year.
  • Current Assets hit $605000.0 in Q4 2025 for Guided Therapeutics, down from $799000.0 in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $3.5 million in Q3 2022 to a low of $605000.0 in Q4 2025.
  • Historically, Current Assets has averaged $1.5 million across 5 years, with a median of $1.4 million in 2021.
  • Biggest five-year swings in Current Assets: surged 705.04% in 2021 and later plummeted 54.8% in 2023.
  • Year by year, Current Assets stood at $1.6 million in 2021, then soared by 83.51% to $3.0 million in 2022, then tumbled by 53.63% to $1.4 million in 2023, then fell by 14.07% to $1.2 million in 2024, then tumbled by 49.46% to $605000.0 in 2025.
  • Business Quant data shows Current Assets for GTHP at $605000.0 in Q4 2025, $799000.0 in Q3 2025, and $811000.0 in Q2 2025.